Gan & Lee Pharmaceuticals
Biopharmaceutical company specializing in insulin analogues and metabolic-disease therapies.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 3 · Recruiting · Primary Hyperlipidemia
Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 DiabetesPhase 3 · Recruiting · Type 2 Diabetes (T2DM)
A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal InsulinPhase 3 · Recruiting · Diabetes
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight SubjectsPhase 3 · Recruiting · Obesity/Overweight in Adult
Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight LossPhase 3 · Recruiting · Overweight or Obesity
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal FunctionPhase 1 · Recruiting · Obesity/Overweight
Selected patent records
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/gan-lee-pharmaceuticals/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.